Keywords: Roche, Trastuzumab emtansine, T-DM1, Breast cancer, Tykerb, GlaxoSmithKline, Genentech

Roche to file for trastuzumab emtansine this year, on positive Ph III results

Article | 03 April 2012

Print This

Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III study of trastuzumab ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in